Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

ADVERTISEMENT

FDA approves Tecelra (a T cell receptor gene therapy) for Synovial Sarcoma 

Tecelra (afamitresgene autoleucel), a gene therapy for the treatment of adults with metastatic synovial sarcoma has been approved by the FDA. The approval was based on assessment of safety and effectiveness in a multicentre, open-label clinical trial. It is the first FDA-approved T cell receptor (TCR) gene therapy.  

Administered as a single IV dose, Tecelra is an autologous T cell immunotherapy made of a patient’s own T cells which are modified to express a TCR that targets MAGE-A4 antigen expressed by cancer cells in synovial sarcoma.  

Nausea, vomiting, fatigue, infections, fever, constipation, shortness of breath, abdominal pain, non-cardiac chest pain, decreased appetite, fast heart rate, back pain, hypotension, diarrhoea and swelling are most common adverse reactions associated with this treatment. Patient may experience a dangerous type of aggressive immune system response and may also exhibit Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS). Hence, patients receiving this treatment should be monitored and are advised not to drive or engage in hazardous activities for at least four weeks after receiving Tecelra. 

Synovial sarcoma is a rare form of cancer in which malignant cells develop and form a tumour in soft tissues. It can occur in many parts of the body, most commonly developing in the extremities. It is a potentially life-threatening cancer and have a devastating impact on individuals. Each year, synovial sarcoma impacts about 1,000 people in the U.S. and most often occurs in adult males in their 30s or younger.  

Treatment typically involves surgery to remove the tumour and may also include radiotherapy and/or chemotherapy. Approval of Tecelra provides a new option for the affected people who often face limited treatment options.  

The approval of Tecelra has been granted to Adaptimmune, LLC. 

*** 

References:  

  1. FDA Approves First Gene Therapy to Treat Adults with Metastatic Synovial Sarcoma. Published 02 August 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-metastatic-synovial-sarcoma  

*** 

SCIEU Team
SCIEU Teamhttps://www.ScientificEuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Most Popular Articles

Skin-attachable Loudspeakers and Microphones

A wearable electronic device has been discovered which can...

Discovery of Interior Earth Mineral, Davemaoite (CaSiO3-perovskite) on Earth’s surface

The mineral Davemaoite (CaSiO3-perovskite, the third most abundant mineral in lower...

Several Coronal Mass Ejections (CMEs) from The Sun Observed  

At least seven coronal mass ejections (CMEs) from the...
- Advertisement -
93,385FansLike
47,372FollowersFollow
1,772FollowersFollow
30SubscribersSubscribe